ArticleJournal of ovarian research2025
Ovarian cancer metastasis to axillary node without breast involvement: a rare case.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is the most lethal gynaecological cancer globally. Despite advanced multimodality treatment 5year survival is around 50% and its only 31% in stage IV cancers. There is no clearly defined precursor lesion. The events which led to metastasis is not clearly understood. Epithelial ovarian cancers (EOC) are the most common type of ovarian malignancy. Stage IV ovarian cancer incidence are raising day by day. Peritoneum is the most common site of recurrence followed by nodes and intra-abdominal metastasis. Distant metastasis outside abdomen is rare. Moreover, ovarian cancer with metastasis to axillary lymph node is very rare presentation specially when breast is not involved. CASE PRESENTATION: We like to report a case of 54year old lady, who was admitted with persistent Right axillary lymph nodal mass. She had a history of High grade serous ovarian cancer stage IVB which was detected and treated 3 years back with neoadjuvant chemo followed by interval cytoreductive surgery followed by Adjuvant multiple line of chemo and maintenance bevacizumab. During follow up, patient had increased Ca-125, and PET CT suggestive of persisting right axillary LN with retroperitoneal LN and right external iliac node. The axillary node was biopsied and found to be metastatic High-grade Serous Ovarian Carcinoma, but mammography showed no abnormality in bilateral breasts. Patient received 2nd line chemotherapy. Secondary Cytoreductive Surgery and HIPEC (cisplatin) and Right Level I ALND done in Department of Surgical Oncology AIIMS, New Delhi. Intraoperatively 3 × 3 cm Right axillary level I single node found. Excision of metastatic axillary node shows excellent result.
conclusionThis case highlights the importance of meticulous evaluation of patient presenting with axillary lymphadenopathy to rule out possibility of ovarian cancer. Additionally, axilla should also be considered as a possible site of metastasis in a known case of carcinoma ovary for effective treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.